Post marketing surveillance of captopril (for hypertension): a preliminary report.
Open Access
- 1 September 1987
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 24 (3) , 343-349
- https://doi.org/10.1111/j.1365-2125.1987.tb03179.x
Abstract
1 The methodology and interim results of a post marketing surveillance of captopril, the first orally active angiotensin converting enzyme inhibitor are presented. 2 Utilising viewdata technology, details of hypertensive patients were entered directly into a mainframe computer. This allowed day to day monitoring of events; a facility not available with paper‐based methods. 3 The design of the study allowed analysis of results including some details of efficacy, concomitant therapy, any disease symptoms and reasons for withdrawal. These factors could be categorised according to sex and age. 4 This preliminary report is based on the first 13,295 patients entered from July 1983 with follow‐ up until January 1985. The results of the study confirm the safety of captopril in the patients studied.This publication has 15 references indexed in Scilit:
- The Effects of Antihypertensive Therapy on the Quality of LifeNew England Journal of Medicine, 1986
- Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up.BMJ, 1985
- ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: PAST, PRESENT, AND BRIGHT FUTUREThe Lancet, 1985
- Postmarketing surveillance: practical experience with ketotifen.BMJ, 1984
- Postmarketing surveillance of the safety of cimetidine: 12 month mortality report.BMJ, 1983
- Post-marketing surveillance: how many patients?Trends in Pharmacological Sciences, 1981
- Post-marketing surveillance of adverse reactions to new medicines.BMJ, 1977
- Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?BMJ, 1977
- Monitoring adverse reactions to drugs.BMJ, 1977
- DRUG RASH WITH AMPICILLIN AND OTHER PENICILLINSThe Lancet, 1969